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Increasing evidence suggests that long non-coding
RNAs (LncRNAs) represent a new class of regula-
tors of stem cells. However, the roles of LncRNAs
in stem cell maintenance and myogenesis remain
largely unexamined. For this study, hundreds of
intergenic LncRNAs were identified that are ex-
pressed in myoblasts and regulated during differen-
tiation. One of these LncRNAs, termed LncMyoD, is
encoded next to the Myod gene and is directly
activated by MyoD during myoblast differentiation.
Knockdown of LncMyoD strongly inhibits terminal
muscle differentiation, largely due to a failure to
exit the cell cycle. LncMyoD directly binds to
IGF2-mRNA-binding protein 2 (IMP2) and negatively
regulates IMP2-mediated translation of proliferation
genes such as N-Ras and c-Myc. While the RNA
sequence of LncMyoD is not well conserved be-
tween human and mouse, its locus, gene structure,
and function are preserved. The MyoD-LncMyoD-
IMP2 pathway elucidates a mechanism as to how
MyoD blocks proliferation to create a permissive
state for differentiation.
INTRODUCTION
Long non-coding RNAs (LncRNAs) constitute a new class of
genes recently identified in various tissues (Cabianca et al.,
2012; Guttman et al., 2009, 2011; Huarte et al., 2010; Lee,
2012; Ørom et al., 2010; Rinn et al., 2007; Tsai et al., 2010).
Thousands of LncRNAs have been annotated in various cells,
but few have been functionally studied. LncRNAs play impor-
tant roles in normal physiology as well as in many diseases,
including embryonic stem cell maintenance, organ develop-
ment, and cancer progression (Gupta et al., 2010; Guttman
et al., 2011; Klattenhoff et al., 2013; Loewer et al., 2010; Na-
gano et al., 2008; Pasmant et al., 2007; Yildirim et al., 2013).
However, the number of LncRNAs expressed in skeletal mus-
cle stem cells and the determination as to whether they areDevebiologically important remains largely unknown (Cesana
et al., 2011; Mousavi et al., 2013). In additional, few function-
ally conserved LncRNAs between mouse and human have
been identified.
While many early studies have been focused on LncRNAs’
roles in epigenetic modification, it is clear that LncRNAs are
a large collection of functionally diverse genes that regulate
biology through many additional mechanisms (Wang and
Chang, 2011). In addition to their roles in epigenetic regulation,
they may also participate in regulating RNA transcription,
splicing and trafficking, RNA stability, microRNA regulation,
translation, etc. (Wang and Chang, 2011). It is important to iden-
tify new protein-binding partners of LncRNAs and mechanisms
of LncRNA biology to help categorize LncRNAs into functional
families.
Myogenesis is a highly coordinated process that includes
sequential steps of activation of muscle stem cells, prolifera-
tion and then differentiation of myoblasts, and cell fusion to
form multinucleated myotubes (Berkes and Tapscott, 2005).
Of all the factors that have been identified in regulating myo-
genesis, MyoD is one of the most critical transcriptional fac-
tors (Berkes and Tapscott, 2005). Overexpression of MyoD
alone is sufficient to reprogram fibroblasts into muscle cells
(Tapscott et al., 1988; Choi et al., 1990). MyoD is particularly
important in myoblasts and controls early myogenesis (Berkes
and Tapscott, 2005), which requires both myoblast cell-cycle
arrest and initiation of a differentiation program. It is well
established that MyoD can induce myoblast differentiation by
activating downstream myogenic factors such as myogenin.
However, how MyoD controls myoblast cell-cycle exit, a
crucial step in myogenesis, is not entirely understood (Cre-
scenzi et al., 1990).
In the current study, we sought to identify novel and
functionally important LncRNAs during myogenesis. We
identified hundreds of LncRNAs that are actively regulated in
myoblasts. Further, we determined through loss-of-function
experiments that LncMyoD is a key downstream target of
MyoD and an important regulator of myoblast cell-cycle exit
and myogenesis. We also demonstrate that human LncMyoD
and mouse LncMyoD are functionally conserved without
strong sequence homology, supporting the argument that
RNA sequence conservation is not indicative of LncRNA
function.lopmental Cell 34, 181–191, July 27, 2015 ª2015 Elsevier Inc. 181
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Figure 1. Identification and Characteriza-
tion of LncMyoD
(A) A total of 1,183 LncRNAs were identified from
skeletal muscle as regions of contiguous coverage
in mRNA-seq data from undifferentiated and
differentiated C2C12 cells. Most of these were
found to be expressed at similar levels in myo-
blasts and myotubes (black dots), while subsets
were either enriched in undifferentiated myo-
blasts (pink dots) or differentiated multi-nuclear
myotubes (green dots). LncMyoD was one of the
top LncRNAs that was found to be highly enriched
in myotubes.
(B) LncMyoD locates next to the MyoD gene on
mouse chromosome 7. LncMyoD is encoded by
the () DNA strand, whileMyoD is coded by the (+)
DNA strand.
(C) 50 RACE and 30 RACE of LncMyoD in my-
otubes.
(D) LncMyoD and LncMyoD* both contain two
exons and share the second exon. LncMyoD is
the major isoform and accounts for 90% of the
transcripts.
(E) LncMyoD was enriched in myotube nuclei,
since about 70% of the spliced LncMyoD was
located in the nucleus. LncMyoD mRNA levels
were upregulated during myoblast differentiation.
*p < 0.05. Error bars depict mean ± SEM.
(F) LncMyoD and LncMyoD* were predicted to be
non-coding RNAs. The RNA sequences of
LncMyoD, MyoD, and HOTAIR were put into the
Coding Potential Calculator (CPC) program, and
both LncMyoD and HOTAIR were predicted to be
non-coding RNAs, whileMyoD RNA was identified
to code for protein.RESULTS
Identification of Skeletal Muscle LncRNAs, Including
LncMyoD
To systematically identify LncRNAs in the skeletal muscle sys-
tem, we analyzed deep RNA sequencing (RNA-seq) data from
C2C12 myoblasts and early myotubes (3 days after differentia-
tion) (Trapnell et al., 2010). After eliminating protein-coding
genes, 1,183 intergenic LncRNAs and 27 microRNA precursors
were found to be expressed in C2C12 cells (Figure 1A; Table
S1). Most of the identified microRNAs have been previously
shown to be expressed and to play important roles in muscle dif-
ferentiation, such as Mir1, Mir24, Mir27, Mir133, Mir205, and
Mir296 (Figure S1A) (Chen et al., 2006; Ge and Chen, 2011).
Among the 1,183 LncRNAs identified, 738 were expressed
at similar levels before and after myoblast differentiation
(myoblasts versusmyotubes) (Figure 1A; Table S1). Interestingly,182 Developmental Cell 34, 181–191, July 27, 2015 ª2015 Elsevier Inc.there were 51 LncRNAs that were
enriched in myoblasts (downregulated
during differentiation) and 394 LncRNAs
that were enriched in myotubes (upregu-
lated during differentiation) (Figure 1A;
Table S1).
We first focused our study on those
LncRNAs that were temporally regulated
during myoblast differentiation becausethey could serve as regulators of myogenesis. Since many
LncRNAs have been shown to either positively or negatively
regulate neighbor genes (Ørom et al., 2010; Rinn et al., 2007;
Tsai et al., 2010), the genomic locations of these were further
characterized. Furthermore, recently, it was pointed out that
many regulatory RNAs seem to be expressed proximal to the
muscle regulatory genes that regulate myogenesis: MyoD and
myogenin. These ‘‘eRNAs’’ include long non-coding RNAs that
act in cis and trans (Mousavi et al., 2013). We, therefore, decided
to focus on one LncRNA in particular that is located about 30 kb
upstream of the mouseMyod1 gene (Figure 1B) and named this
LncRNA LncMyoD.
Characterization of the LncMyoD Sequence and
Expression Pattern
50 RACE (Rapid Amplification of cDNA Ends) and 30 RACE
demonstrated that the length of LncMyoD was 622 base pairs
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Figure 2. Expression Pattern of LncMyoD in
Different Tissues and duringMuscle Regener-
ation In Vivo
(A) LncMyoD expression was only detected in
myoblasts and early myotubes, but not in any other
tissues examined, including ovary, liver, lung,
spleen, embryo, kidney, heart, thymus, brain and
(notably) mature skeletal muscle. Error bars depict
mean ± SEM.
(B) Skeletal muscles were injected with CTX, and
samples were harvested at different time points from
day 0 to day 14. Tissue samples were stained by
H&E and the staining clearly demonstrated the steps
of muscle regeneration from intact muscle (day 0),
tissue damage (day 1), myoblast proliferation (day 3),
muscle differentiation (days 5–7) and completed
regeneration (day 14).
(C) LncMyoD was induced after muscle injury
and mirrored the MyoD mRNA expression pattern
during skeletal muscle regeneration. LncMyoD was
strongly upregulated at day 3 and day 5 after
CTX-induced muscle regeneration and began to
decrease after day 7. Skeletal muscle mRNAs were
extracted from two animals at each time point during
muscle regeneration. Error bars depict mean ± SEM.(bp) (Figures 1C and S1B). The gene contains two exons and one
intron (Figure 1D), and, like many LncRNAs, it is poly(A) tailed
(Figure S1C). We also identified a minor isoform (10% of the
RACE product), termed LncMyoD*, that shares the large Exon2
with LncMyoD but has a different Exon1 (Figures 1D and S1B).
LncMyoD was not previously annotated, and LncMyoD* signifi-
cantly overlaps with a known transcript AK006355. Both
LncMyoD and LncMyoD* are strongly upregulated upon differen-
tiation from myoblasts to myotubes (Figures 1A, S1A, and S1C).
Cell fractionation followed by qRT-PCR demonstrates that about
70% of the spliced LncMyoD transcript resides in the nucleus
(Figure 1E). Consistent with LncMyoD being a non-coding
RNA, it harbors no open reading frames (ORFs) larger than
200 bp; the CPC (coding potential calculator) computational
algorithm (Kong et al., 2007) predicts that LncMyoD has a very
low coding potential, similar to HOTAIR, a well-known LncRNA
(Figure 1F). We found no evidence of a protein product from
LncMyoD, using an in vitro translation system (data not shown).Developmental Cell 34, 181We next examined the expression profile
of LncMyoD in multiple adult tissues.
LncMyoD was not expressed in any adult
tissues tested (Figure 2A). Interestingly, like
MyoD, LncMyoD is not expressed in mature
skeletal muscle (Figure 2A), suggesting
that the gene is temporally upregulated
during early differentiation of myoblasts to
myotubes but eventually turned off as the
muscle matures into post-differentiated
muscle fibers. To test the correlation be-
tween LncMyoD levels and differentiation
in vivo, the gene was examined during a
period of induced muscle regeneration,
using a cardiotoxin (CTX)-injury assay (Fig-
ure 2B). The LncMyoD level was low in unin-jured muscle and strongly upregulated at 3–5 days after muscle
injury. It began to be downregulated after day 5, when themuscle
regeneration entered the late stage (Figure 2C). Notably, this
expression pattern is almost identical to that ofMyoDmRNA (Fig-
ure 2C). While the LncMyoD* level was significantly lower in all
experiments, it followed the same expression pattern as that of
LncMyoD (Figures 2A and 2C).
LncMyoD Is a Direct Target of MyoD
To determine the upstream factor (or factors) regulating
LncMyoD during myogenesis, we analyzed the 50 and intron
sequences of the gene and found that there are six canonical
MyoD binding sites (E-Boxes) in this region (Figures S2A and
S2B), raising the possibility that LncMyoD is a direct target of
MyoD. Such a finding would be consistent with the coincident
expression profiles of LncMyoD and MyoD. Knocking down or
overexpressing MyoD led to downregulating or upregulating
LncMyoD transcription, respectively (Figure 3A).–191, July 27, 2015 ª2015 Elsevier Inc. 183
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Figure 3. MyoD Binds to the LncMyoD
Promoter and Directly Activates LncMyoD
Transcription
(A) MyoD regulates LncMyoD at the transcriptional
level. Knocking down or overexpressing MyoD,
respectively, downregulates or upregulates
LncMyoD and pre-LncMyoD. *p < 0.05. Error bars
depict mean ± SEM.
(B) The LncMyoD promoter could be activated by
MyoD. A LncMyoD-Pro-Luciferase construct
demonstrated a dose-dependent activation byMyoD
protein. When the promoter was reversed, its activity
significantly decreased, and the response to MyoD
was modest. *p < 0.05. Error bars depict mean ±
SEM.
(C) MyoD bound to E-boxes on the LncMyoD
promoter. ChIP experiments indicated that MyoD
bound to the first and last E-Boxes on the LncMyoD
promoter regions in vivo. Notably, such binding was
stronger in myotubes than in myoblast. *p < 0.05.
Error bars depict mean ± SEM.We next cloned the LncMyoD regulatory element into a
PGL3 luciferase reporter construct. When the reporter was co-
transfected with a MyoD overexpression construct, it showed
dose-dependent activation by MyoD (Figure 3B), suggesting
that MyoD could directly promote LncMyoD transcription. Unlike
enhancers, the activity of a promoter is usually orientation
dependent. Consistent with this, the ‘‘reverse reporter’’ had
much weaker baseline activity and could only be modestly acti-
vated by MyoD (Figure 3B). To directly determine which site(s)
MyoD binds to within the LncMyoD promoter, chromatin immu-
noprecipitation (ChIP) was performed. MyoD was found to
strongly bind to a 50 E-Box tandem and 30 E-Box tandem in the
LncMyoD promoter (Figure 3C). Importantly, the binding of
MyoD was significantly weaker in myoblasts than in myotubes,184 Developmental Cell 34, 181–191, July 27, 2015 ª2015 Elsevier Inc.consistent with low expression of LncMyoD
in myoblasts (Figures 1A and 1E). Together,
these data demonstrate that LncMyoD is a
direct MyoD target.
LncMyoD Is Required for Myoblast
Differentiation without Altering MyoD
mRNA or Protein Level
The expression profile of LncMyoD
prompted us to investigate its function
during muscle differentiation. Two doxycy-
cline (Dox)-inducible shRNAs successfully
knocked down LncMyoD levels by more
than 80% (Figure 4A). When myoblasts
were induced to differentiate, knockdown
of LncMyoD resulted in significant inhibition
of terminal differentiation, as demonstrated
by the reduced Myosin Heavy Chain (MHC)
stainingcoincidentwith theknockdown (Fig-
ure 4B). After LncMyoD knockdown, a high
percentage of myoblasts initially maintained
an undifferentiated, round morphology (Fig-
ure S3A) and still expressed relatively high
levels of Ki67 (a marker of proliferation),even while in differentiation medium (Figure 4C), suggesting that
LncMyoD is essential for cell-cycle withdrawal, a key step in
myoblast differentiation.
Notably, while LncMyoD knockdown blocked myoblast
differentiation, it did not change MyoD mRNA (Figure S3B) or
protein levels (Figure 4D). This finding is consistent with the
idea that MyoD is upstream of and regulates LncMyoD and
that there is no feedback signaling of LncMyoD to MyoD,
thus suggesting that LncMyoD is different from other MyoD
neighbor LncRNAs (Mousavi et al., 2013) and leaving open
the question of the downstream pathway controlled by this
LncRNA.
In order to perform an unbiased search for downstream
signaling pathways perturbed by LncMyodD downregulation,
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Figure 4. LncMyoD Plays Important Roles in
Myoblast Differentiation
(A) Knockdown of LncMyoD using inducible
shRNAs. Two different Dox-inducible shRNAs
targeting LncMyoD successfully knocked down
LncMyoD levels by more than 80% after Dox
treatment. NT shRNA was used as control. *p <
0.05. Error bars depict mean ± SEM.
(B) Knockdown of LncMyoD inhibited myoblast
differentiation. Myoblasts stably infected with
either LncMyoD or NT shRNAs were induced to
differentiate, with or without Dox treatment. Three
days after differentiation, cells were fixed and
stained for MHC, a marker of terminal muscle dif-
ferentiation. The percentage of nuclei that were
associated with MHC-positive staining was
significantly reduced by the LncMyoD shRNAs but
not by the NT shRNA. *p < 0.05. Error bars depict
mean ± SEM.
(C) LncMyoD knockdown leads to increased
Ki67 expression and decreased myogenin acti-
vation during myoblast differentiation. Myoblasts
stably infected by LncMyoD or NT shRNAs were
induced to differentiate with or without Dox
treatment. 48 hr after differentiation, protein
samples were harvested, and Ki67, myogenin,
MuRF1, and MAFbx proteins were detected by
western blots. Tubulin was used as a loading
control.
(D) LncMyoD knockdown does not regulate MyoD
protein levels. Western blots demonstrated that
MyoD protein levels remained consistent before
and after LncMyoD knockdown, suggesting that,
unlike some LncRNAs, LncMyoD does not directly
regulate the expression of its closest neighbor
gene MyoD. Histone 3 (H3) was used as a loading
control.
(E) Knockdown of LncMyoD leads to a reduction of
myogenic genes. A heatmap indicates that, after
LncMyoD shRNA treatment, a large number of
genes were perturbed. Notably, multiple genes
involved in muscle functions, including Ckm,
Slc2a4, Jph1, Srl, and Col6a1, were significantly
downregulated, consistent with decreased
myoblast differentiation.microarrays were performed on myoblasts treated with control
versus LncMyoD shRNAs. LncMyoD shRNAs altered the levels
of hundreds of mRNAs (Figure 4E; Table S2). Muscle differentia-
tion markers Creatine Kinase Muscle (CKM) and Myosin Heavy
Chain 1 (MHC1) are among the most downregulated genes (Fig-
ure 4E). Further, we looked at myogenin, MuRF1, and MAFbx as
additional markers of differentiation (Bodine et al., 2001) and
found that these too were regulated by knockdown of LncMyoD
(Figure 4C). When grouped by biological role, genes involved in
skeletal muscle-specific functions, such as muscle contractility
and myofibril-specific proteins, were among the most downre-
gulated by LncMyoD knockdown (Table S3). These data further
confirmed that LncMyoD is required for muscle differentiation,
establishing differentiation-specific genes as markers of the
knockdown.DeveIdentification of Functionally Conserved Human
hLncMyoD
LncRNAs are generally poorly conserved at the RNA sequence
level, and no homolog of mouse LncMyoD was identified in
human when we ran a BLAST analysis. However, a few posi-
tion-conserved LncRNAs are also conserved in function (Ulitsky
et al., 2011). In addition, during our study of LncMyoD regulation
by MyoD, we noticed that MyoD binding sites are highly
conserved across many mammalian species, including human
(Figure 5A). This suggests that human MyoD might also regulate
an important gene at that locus. By specifically analyzing human
RNA-seq data surrounding the genome locus of MYOD1 in
human chromosome 11, we identified a LncRNA (which we
have termed hLncMYOD), located about 20 kb upstream of
the human MYOD1 gene—very similar to mouse LncMyoD’slopmental Cell 34, 181–191, July 27, 2015 ª2015 Elsevier Inc. 185
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Figure 5. Identification of Human
hLncMyoD
(A) MyoD binding sites on LncMyoD promoter are
conserved in human and other mammals. Cons
score, conservation score.
(B) Location and exon structure of human
hLncMyoD.
(C) Conserved function of LncMyoD between
mouse and human. LncMyoD shRNA-treated my-
otubes were transfected with plasmid as indicated.
Cells were harvested, qRT-PCRs were performed
to measure each RNA level, and western blots
were performed to detect MHC. Ponceau S stain-
ing was used as a loading control. endo+exo,
endogenous plus exogenous.location relative to mouse MyoD1. RACE experiments showed
that human hLncMYOD is a transcript of 600-bp length and con-
taining three exons (Figures 5B and S4A).
To investigate whether LncMyoD functions are conserved
between mouse and human, we overexpressed either mouse
LncMyoD or human hLncMYOD exogenously in mouse
LncMyoD knockdown myoblasts. Overexpression of LncMyoD
alone has little effect on MHC expression, suggesting that it is
required but not sufficient to drive differentiation (Figure S4B).
Remarkably, both mouse LncMyoD and human hLncMYOD
can restore the expression of MHC after endogenous mouse
LncMyoD’s downregulation (Figures 5C and S4C). This suggests
that LncMyoD function in myoblast differentiation is conserved
between mouse and human.
LncMyoD Binds to IMPs and Regulates mRNA
Translation
To further investigate the mechanism by which LncMyoD may
regulate the cell cycle and myoblast differentiation, we attemp-186 Developmental Cell 34, 181–191, July 27, 2015 ª2015 Elsevier Inc.ted to identify LncMyoD-interacting
proteins, using a biotinylated-LncMyoD
protein pull-down assay. Both non-bio-
tinylated LncMyoD and biotinylated
antisense RNA were used as controls.
After screening a set of RNA-binding
proteins, IGF2 mRNA-binding proteins
(IMPs) were found to strongly bind to
LncMyoD (Figure 6A). As a specificity
control, the antisense strand was also
used, and this did not pull down the
IMPs (Figure 6A), demonstrating that
the interaction is specific to the ‘‘sense’’
strand of the LncMyoD. The IMP family
has three members: IMP1, IMP2, and
IMP3. While we confirmed that LncMyoD
at least binds to both IMP1 and IMP2,
we focused our efforts on IMP2,
because this protein has been shown
to be required for myogenesis as a
result of its binding and upregulating
the translation of proliferation-relevant
target mRNAs (Boudoukha et al., 2010;
Li et al., 2012).It was important to determine whether IMP2 and LncMyoD
interact in vivo; therefore, endogenous IMP2 protein was immu-
noprecipitatedusingan IMP2antibody,andLncMyoDwas indeed
detected in the complex (Figure 6B). IMPs contain four signature
K-homology-type (KH-type) RNA-binding domains and bind to
CAUH (H = A, U, or C) RNA sequences (Hafner et al., 2010).
Notably, LncMyoD contains multiple potential IMP-binding se-
quences (Figure S5A), and only full-length, but not truncated, var-
iants of LncMyoD can rescue the downregulation of endogenous
LncMyoD (Figure S6). The direct binding of LncMyoD to IMP2
raised the possibility that LncMyoD may regulate IMP2 protein
levels and/or function. We first examined the protein level of
IMP2 usingwestern blot analysis and found that LncMyoD knock-
down caused an increase in IMP2 protein levels (Figure 6C); this
increase was not due to the upregulation of transcription or pro-
tein stability (Figure S7). Immunofluorescence demonstrated
that IMP1 and IMP2proteinswere strongly enriched in the perinu-
clear space after LncMyoD knockdown (Figures S5A and S5B).
Interestingly, IMP2 bound to its ownmRNA, suggesting a positive
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Figure 6. LncMyoD Regulates IMP Function
(A) LncMyoD bound to IMP1 and IMP2. Biotinylated
LncMyoD was pulled down by streptavidin beads,
and co-eluted proteins were detected by western
blot. Non-biotinylated LncMyoD and biotinylated
antisense-LncMyoD were used as controls.
(B) LncMyoD bound to IMP2. IMP2 immunoprecipi-
tation was performed using antibodies against IMP2.
RNAs interacting with IMP2 were eluted, reverse
transcribed, and quantified by real-time PCR.
*p < 0.05. Error bars depict mean ± SEM.
(C) Knockdown of LncMyoD upregulated IMP2,
NRAS, andMYCproteins. Dox-induced shRNAswere
used to knock down LncMyoD. IMP2, NRAS, and
MYC proteins were detected by western blot.
a-Tubulin was used as a loading control.
(D) LncMyoD knockdown caused a significant in-
crease in the binding of IMP2 to many target mRNAs,
including Myc, Ccng1, Igf1r, Igf2, Nras, and Rhla.
IMP2 immunoprecipitation was performed using
antibodies against IMP2. RNAs interacting with
IMP2were eluted, reverse transcribed, and quantified
by real-time PCR. *p < 0.05. Error bars depict
mean ± SEM.feedback loop where IMP2 protein can modulate the stability
and/or translation of its own mRNA (Figure 7A). Knockdown of
LncMyoD enhanced the interaction between IMP2 and Imp2
mRNA, which helps to explain the upregulation of IMP2 protein
levels (Figures 6B and 6C). IMP1 protein showed a similar but
modest upregulation after LncMyoD knockdown, suggesting
that LncMyoDmay regulate multiple IMPs (Figure S5C).
IMP2 regulates myoblast growth through binding to and
enhancing the translation of mRNAs involved in proliferation,
such as Nras and Myc (Li et al., 2012). LncMyoD knockdown
caused a significant increase in the binding of many target
mRNAs to IMP2, including Myc, Ccng1, Igf1r, Igf2, Nras, and
Rhla (Figure 6D). Consequently, proteins like NRAS and MYC
were maintained at high levels even upon differentiation stimuli
(Figure 6C),which could contribute to the failure of terminal differ-
entiation, given the undifferentiated phenotype of the LncMyoD
knockdown myoblasts (Figure 4B). However, knocking down
IMP2 by siRNA could not rescue the phenotype of LncMyoD
knockdown (data not shown) which indicates that LncMyoD reg-
ulates more than just IMP2 during differentiation (for example, as
noted, we also showed that it can regulate IMP1 as well).
Finally, we pulled down the IMP2/RNP complex from myo-
blasts and myotubes at different time points. qRT-PCR showed
that the increase of LncMyoD enlarged the amount of IMP2
bound, competing out other mRNAs including Imp2, Myc,
Ccng1, Igf1r, Igf2, and Nras (Figure 7A). Taken together, our
data suggest that induction of LncMyoD could perturb the pos-
itive feedback of IMP mRNA and IMP protein and, therefore,
facilitate cell-cycle exit and promote terminal differentiation.
DISCUSSION
The number of LncRNAs identified in the human has been found
to be comparable to the number of protein-coding genes (Vold-Deveers et al., 2013), yet only a small fraction of the LncRNA genes
have been functionally studied. In this paper, we report the iden-
tification of LncMyoD, a muscle-specific LncRNA that targets
MyoD and functions as a regulator of myogenesis. We further
use RNA pull-down experiments to identify IMPs as important
binding partners of LncMyoD. To our knowledge, LncMyoD is
the first long non-coding RNA that has been shown to act by
blocking IMP-mediated shuttling of particular RNAs; it thus in-
hibits translation and thereby perturbs the many genes that
require IMP for efficient translation.
One of the interesting findings in this study is that the human
homolog of LncMyoD, hLncMyoD, could rescue the myogenesis
deficiency in mouse myoblasts depleted of mouse LncMyoD.
This demonstrates that LncMyoD gene function is conserved
between human and mouse. hLncMyoD and LncMyoD genome
locations are conserved, and the MyoD-binding sites on their
promoters are highly conserved, strongly suggesting that
LncMyoD is a functionally important target of MyoD. However,
despite the location and functional conservation, the sequence
homology between hLncMyoD and LncMyoD is low. This finding
is consistent with previous reports that LncRNAs and mRNAs
face distinct selection pressures during evolution and that
sequence conservation is not a good filter for functionally impor-
tant LncRNAs (Ulitsky et al., 2011). In fact, the primary RNA
sequences of XIST and TERC, two of the best studied mamma-
lian LncRNAs, are not conserved between mouse and human;
however, their functions are the same and crucial in both spe-
cies. It is thought that LncRNA conservation is at the secondary
or tertiary level, and recent structure biology work on the telome-
rase RNA component-telomerase reverse transcriptase (TERC-
TERT) complex supports this notion (Huang et al., 2014).
We have previously shown that the DNA hook protein HMGA2
mediates IMP2 activation in skeletal muscle (Li et al., 2012)
and that this is required to maintain activated satellite cells in alopmental Cell 34, 181–191, July 27, 2015 ª2015 Elsevier Inc. 187
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Figure 7. LncMyoD Contributes to Myogene-
sis by Competing for IMP2 Binding
(A) LncMyoD competes for IMP2 binding. IMP2RNP
complex were pulled down from myoblast or
myotubes at different time points. qRT-PCRs were
performed to analyze RNA from input and co-eluted
with IMP2. DM, differentiation media. *p < 0.05.
Error bars depict mean ± SEM.
(B) Model of the MyoD-LncMyoD-IMP pathway in
promoting muscle differentiation. LncMyoD is
induced by MyoD and competes with mRNAs like
c-Myc and N-Ras for IMP binding. This leads to
reduced mRNA translation, cell-cycle exit, and
myoblast differentiation.proliferation state. The finding of LncMyoD adds another regula-
tory node to translation of IMP2-chaperoned proteins, establish-
ing an HMGA2/IMP2/LncMyoD pathway. Other MyoD-localized
LncRNAs could also perturb muscle differentiation (Mousavi
et al., 2013), by both cis and trans mechanisms; for example, it
was also reported that LncRNA could regulate myogenesis by
working as a microRNA sponge (Cesana et al., 2011). It will be
of interest to see whether there is any crosstalk between these
LncRNAs or whether the newly discovered IMP2 binding is a
mechanism particular to the MyoD-LncMyoD-IMP pathway (Fig-
ure 7B). Since IMPs are involved in regulating cell proliferation
and organ development in many tissues (Hansen et al., 2004;188 Developmental Cell 34, 181–191, July 27, 2015 ª2015 Elsevier Inc.Li et al., 2012, 2013), it will be of great inter-
est to identify and study IMP-binding
LncRNAs in other systems.
Disturbedmyogenesismay be a compo-
nent of themechanism of diseases such as
cachexia, sarcopenia, and especially
muscular dystrophy (where a pattern of
muscle breakdown and regeneration re-
peats itself until the muscle’s regenerative
capacity is depleted). The newly identified
MyoD-LncMyoD-IMP pathway provides
an additional mechanism that may be
amenable to intervention in disease set-
tings. We are currently examining the
activity of this pathway in a variety of
muscle diseases in order to determine
whether targeting LncMyoD or LncMyoD-
IMP2 interaction would be beneficial for
patients.
EXPERIMENTAL PROCEDURES
LncRNA Identification
Confluent C2C12 myoblast differentation model
mRNA sequencing (mRNA-seq) raw sequence
read data, from Trapnell et al. (2010) (data series
GSE20846), was downloaded from the Sequence
Read Archive (SRA; http://www.ncbi.nlm.nih.gov/
sra); specifically, data relating to the data series
SRX017794 (‘‘24 hours’’; ref http://www.ncbi.
nlm.nih.gov/sra?term=SRX017794; mouse skeletal
muscle C2C12 cells, exponential growth phase in
high serummedium, taken as amodel of undifferen-
tiated myoblasts) and data series SRX017795 (‘‘+60hours’’; ref http://www.ncbi.nlm.nih.gov/sra?term=SRX017795; confluent
mouse skeletal muscle C2C12 cells, 60 hr post-switch to low serum medium,
initiating myogenic differentiation, taken as a model of differentiated myo-
tubes). SRA data archives were converted to FASTQ format (ref), using the
SRA toolkit, and aligned against the mouse genome (build mm9/ncbim37;
ref http://may2012.archive.ensembl.org/Mus_musculus/Info/Index) using
bowtie (Langmead et al., 2009) and using the ‘‘-m 1 –best’’ flags. In order to
detect transcribed, non-genic regions of the genomes (Mitchell et al., 2012),
SeqMonk software (http://www.bioinformatics.babraham.ac.uk/projects/
seqmonk/) was used, and contiguous regions of genome coverage were iden-
tified. Using a 1-kbp sliding window allowing for 500 bp between reads, each
non-genic region was annotated using the nearest gene feature, and reads per
kilobase per million (RPKM) (Mortazavi et al., 2008) coverage statistics were
calculated.
Protein Extraction and Immunoblotting
Cells were lysed with NP40 buffer (25mMHEPES, 100mMNaCl, 5 mMMgCl2,
10% glycerol, 0.2% NP-40, phosphatase inhibitor cocktail-1 and -2 (Sigma)
and protease inhibitor cocktail (Roche) for total protein characterization.
When nuclear extraction was required, cells were extracted using a CHEMI-
CON Nuclear Extraction Kit (Millipore, #2900). Equal amounts of cell lysate
were resolved by SDS-PAGE, transferred to polyvinylidene difluoride mem-
branes (Millipore), and detected using an enhanced chemiluminescence
system (Pierce Biotechnology). Primary antibodies used were p62 (Abcam,
#ab24609), GAPDH (Cell Signaling, #5174), Ki67 (Abcam, #ab15580), Myoge-
nin (BD Pharmingen, #556358), MuRF1 (Abcam, #ab172479), MAFbx (Abcam,
#ab168372), Tubulin (Abcam, #ab6160), MyoD (Santa Cruz Biotechnology,
#sc760), H3 (Cell Signaling, #9517), MHC (Millipore, #05-833), IMP1 (Cell
Signaling, #2852), IMP2 (MBL, #RN008P), NRas (Santa Cruz, #sc31), and
cMyc (Cell Signaling, #5605).
Muscle Regeneration
Muscle degeneration/regeneration by cardiotoxin (CTX)-mediated injury was
performed as previously described (Li et al., 2012). In brief, left TA muscles
of anesthetized 8- to 12-week-old C57BL/6 WT or Hmga2 KOmice were intra-
muscularly injected with 100 ml of 10 mMNaja mossambica mossambica CTX.
Right TA muscles of the same mice were injected with PBS as control. Muscle
samples were harvested for immunohistochemistry at day 0, day 1, day 3,
day 5, day 7, and day 14 after injection and stained with H&E and specific an-
tibodies. Regeneration was clearly activated in the first 3 days and recovered
by 14 days after injury.
Isolation of RNA and RT-PCR
Total RNAs were isolated with RNeasy Kits (QIAGEN), and cDNA was made
using an iScript cDNA Synthesis Kit. SYBR Green dye-based quantitative
real-time PCR was performed using the SYBR Green PCR Master Mix
and 7900HT Fast Real-Time PCR System from Applied Biosystems. Indi-
vidual gene primers were designed and synthesized by Integrated DNA
Technologies.
Immunofluorescence
Staining of differentiating myoblasts was performed as previously described.
Briefly, cells grown in chamber slides were fixed in 4% paraformaldehyde
(PFA) for 15 min in room temperature and permeabilized by 0.5% Triton
X-100. Samples were then stained with primary antibody for 2 hr, andwith sec-
ondary antibody for 30 min at room temperature. Nuclei were labeled with
DAPI. The primary antibody used was MHC (Millipore, #05-833). Anti-mouse
secondary antibody used was from Invitrogen.
30 RACE and 50 RACE
The RNA-ligase-mediated RACE (RLM-RACE) was carried out with total RNA
extracted from primary myoblasts culture and was used to determine the tran-
scription start points and the size of the LncMyoD transcripts. Rapid amplifica-
tion of 50 or 30 cDNA ends was carried out using a FirstChoice RLM-RACE kit
(Ambion), according to the manufacturer’s instructions. Due to the low copy
number of LncMyoD in cells, nested PCR was performed for each reaction.
Primers used are as follows:
50 RACE External (CTA AAG AGA AGC CAG CAG CCA TG);
50 RACE Internal (CCC CAG TCA GGC CTT GAG ATG AG).
30 RACE External (AGC AGC AGC AGG GCT CTG AAG G); and
30 RACE Internal (GGG GAG AAG CCA CAC CCA TC).RNA-Binding Protein Immunoprecipitation
RNA-binding protein immunoprecipitation (RIP) was performed using aMagna
RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore). Briefly, primary
mouse myoblasts were harvested by adding RIP lysis buffer. Clear superna-
tant containing IMP2 protein, Protein G beads, and IMP2 antibody (or immuno-
globulin G [IgG] control) was mixed to perform the immunoprecipitation. After
washing, RNAs binding to IMP2 were eluted and quantified. RT-PCR and
real-time PCR were performed to examine whether certain mRNAs were
co-immunoprecipitated with the IMP2 antibody.DeveMyoblasts Isolation and Culture
The isolation procedure for mouse myoblasts and subsequent pre-plating
methods have been described previously (Li et al., 2012). All procedures were
performed in accordance with the standards of the U.S. Department of Health
and Human Services and were approved by the Novartis Animal Care and Use
Committee. Briefly, limbs of 21-day-old male C57BL/6mice were isolated, and
muscle was pulled from the bone and cartilagewith sterile forceps. Themuscle
was treated for 1 hrwithCollagenase (Sigma) andDispase II (Roche) to degrade
collagenand todisrupt cell contacts. Thecellswereplated for 2 hr to allowfibro-
blasts, which rapidly adhere, to attach to the Petri dish. The supernatant, con-
taining amixture ofmyoblasts and fibroblasts, was removed, and the cellswere
passagedagain to another Petri dish. After 24 hr, the cellswere again passaged
and subsequently transferred to another culture dish. To grow primary myo-
blasts, cellswere cultured in F10 (GIBCO)+20%FBS (GIBCO)+2.5ng/ml basic
fibroblast growth factor (bFGF) (Invitrogen) + 1%penicillin/streptomycin.When
induced for differentiation, myoblasts were switched to differentiation medium
(DMEM supplemented with 5% horse serum).
Luciferase Reporter Assay
LncMyoD forward or reverse promoter regions were cloned into a PGL3 lucif-
erase reporter vector (Promega). To overexpress MyoD protein, the mouse
Myod1 coding region was cloned into the pcDNA3.1(+) vector. LncMyoD-
Pro-Luciferase, Renilla, and MyoD plasmids were transfected into 293 cells
seeded in 96-well plates, using the FUGENE 6 (Roche) transfection reagent,
following the manufacturer’s protocol. 48 hr later, cells were lysed, and lucif-
erase assays were performed using a Dual-Luciferase Reporter Assay System
(Promega) on a luminometer. Transfection of each construct was performed in
triplicate in each assay. Luciferase readings were taken as singlets. Ratios of
Renilla luciferase readings to Firefly luciferase readings were taken for each
experiment, and triplicates were averaged.
Inducible shRNA Knockdown
For knockdown of LncMyoD, ten shRNA sequences targeting LncMyoD were
cloned into a Tet-pLKO-puro vector (Addgene #21915). Lentivirus was pro-
duced using a ViraPower Lentiviral Packaging Mix (Life Technologies) in
293T cells, filtered, and used to infect myoblast cells. The efficacy of shRNA
constructs was screened after Dox treatment for 48 hr followed by RT-PCR.
A non-targeting (NT) shRNA sequence was used as negative control (adapted
from Sigma SHC002). Two shRNAs achieved more than 80% knockdown ef-
ficacy and were, therefore, selected for sequential experiments:
The target sequence for sh-LncMyoD 1# is AGCCTCAGTTTCTTGTC
ATGT.
The target sequence for sh-LncMyoD 2# is GAGTTGTCACCCAAGGC
AAGA.Microarray and Analysis
Total RNAwas extracted using the TRIzol reagent (Invitrogen) and purifiedwith
QIAGEN RNeasy separation columns (QIAGEN). For microarray analysis, first-
strand cDNA was synthesized and hybridized to GeneChip Mouse Genome
430 2.0 Array (Affymetrix).
Statistical analysis of the microarray data was performed within the R statis-
tical environment, using bioinformatics packages from Bioconductor. The raw
signals fromCEL files were normalized and summarized into probe-set level in-
tensities using the PLIER (Probe Logarithm Intensity ERror) method. Affymetrix
MAS5 present/absent calls were calculated, and probe sets with ‘‘present’’
calls in less than 50% of samples within all treatment groups were removed
for further statistical analyses. The moderated F test implemented in the limma
package (Smyth, 2004) was applied to determine the significance of the differ-
ential expression of each probe set between treatments. The p values were
further adjusted using the Benjamini andHochbergmultiple testing procedures
for false discovery rate (FDR) control. Pathway and upsteam regulator analyses
were conducted using Ingenuity Pathway Analysis (Ingenuity Systems).
ChIP
An Active Motif’s ChIP-IT Express Kit was used for the ChIP experiment
according to the manufacturer’s instructions. Briefly, cells were crosslinkedlopmental Cell 34, 181–191, July 27, 2015 ª2015 Elsevier Inc. 189
with 1% formaldehyde for 10 min at room temperature and lysed in SDS lysis
buffer. Samples were then sonicated or enzymatically digested to obtain DNA
fragments with an average length of 200–800 bp. Supernatant containing
DNA-protein complexes was used for immunoprecipitations using an anti-
MyoD antibody (Santa Cruz, sc-760) or a normal rabbit IgG control. Immuno-
precipitated chromatin was collected using protein Gmagnet beads, and, after
washing and elution, reverse crosslinking was carried out with 0.2 M NaCl at
65C overnight. The chromatin was then digested by 20 mg of Proteinase K
(Invitrogen) for 1 hr at 45C and isolated by phenol chloroform extraction.
PCR reactions were performed using the SYBR Green PCR Master Mix
(Applied Biosystems) and primers against LncMyoD promoter regions. Data
were normalized to the input signal and IgG values.
Statistical Analyses
Descriptive statistics were generated for all quantitative data with presentation
of means and SEs. Results were assessed for statistical significance using
Student’s t test (Microsoft Excel) or ANOVA with the SAS Enterprise Guide
3.0 or SigmaPlot 11.0 software.
ACCESSION NUMBERS
The accession number for the microarray data presented in Table S1 of this
paper is NCBI GEO: GSE68842.
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